Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | F10 | P00742 | 6/20 | 0.47 |
| ▸ | LMNA | P02545 | 5/20 | 0.46 |
| ▸ | TP53 | P04637 | 1/20 | 0.46 |
| ▸ | GRM5 | P41594 | 5/20 | 0.45 |
| ▸ | MAPT | P10636 | 2/20 | 0.44 |
| ▸ | LSS | P48449 | 1/20 | 0.44 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.43 |
| ▸ | HCRTR1 | O43613 | 3/20 | 0.42 |
| ▸ | HCRTR2 | O43614 | 3/20 | 0.42 |
| ▸ | POLB | P06746 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7996075 | 0.92 | F10 (0.48) | F10LMNATP53MAPTSMN1; SMN2 | |
| SCHEMBL7999821 | 0.91 | F10 (0.48) | F10LMNATP53GRM5MAPT | |
| SCHEMBL7996031 | 0.90 | HCRTR1 (0.47) | F10LMNATP53MAPTHCRTR1 | |
| SCHEMBL7986948 | 0.89 | GRM5 (0.45) | LMNATP53GRM5MAPTLSS | |
| SCHEMBL7996149 | 0.89 | HCRTR1 (0.46) | LMNATP53GRM5MAPTLSS | |
| SCHEMBL8000009 | 0.88 | LMNA (0.44) | F10LMNATP53GRM5MAPT | |
| SCHEMBL8000061 | 0.87 | HCRTR1 (0.43) | F10LMNATP53MAPTHCRTR1 | |
| SCHEMBL7996072 | 0.86 | LMNA (0.46) | F10LMNATP53MAPTSMN1; SMN2 | |
| SCHEMBL7996147 | 0.86 | LMNA (0.42) | F10LMNATP53MAPTSMN1; SMN2 | |
| SCHEMBL7986759 | 0.83 | MAPT (0.42) | F10LMNATP53GRM5MAPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2000008005-A2 | PIPERAZINONE DERIVATIVES | MERCK PATENT GMBH (DE) | 2000-02-17 | — | — | WO | disclosed |